

Steps before prequalification

I. BACKGROUND INFORMATION ON THE PROCEDURE

1. Submission of the dossier

The company Universal Corporation Limited submitted in 2020 an application for [MA169 trade name]* (MA169) to be assessed with the aim of including [MA169 trade name] in the list of prequalified medicinal products for malaria prevention.

[MA169 trade name] was assessed according to the ‘*Procedure for Assessing the Acceptability, in Principle, of Pharmaceutical Products for Purchase by United Nations Agencies*’ by the team of WHO assessors. The assessors are senior experts, mainly from national authorities, invited by WHO to participate in the prequalification assessment process.

2. Steps taken in the evaluation of the product

July 2020	A desk review for evaluation of compliance for the bioequivalence study for GLP and GCP met WHO requirements.
July 2020	During the meeting of the assessment team the safety and efficacy data were reviewed and further information was requested
July and September 2020	During the meetings of the assessment team the quality data were reviewed and further information was requested.
September 2020	The applicant’s response letter was received.
September 2020	The safety and efficacy data were reviewed and found to comply with the relevant WHO requirements.
January 2021	The applicant’s response letter was received.
January and March 2021	During the meetings of the assessment team the additional quality data were reviewed and further information was requested.
May 2021	The applicant’s response letter was received.
June 2021	The additional quality data were reviewed and further information was requested.
June 2021	A desk review for evaluation of compliance of the manufacturer of the API for GMP was conducted and it met WHO requirements.
September 2021	The applicant’s response letter was received.
September and October 2021	The additional quality data were reviewed and further information was requested.
November 2021	The applicant’s response letter was received.
December 2021	The additional quality data were reviewed and further information was requested.
January 2022	The applicant’s response letter was received.
January 2022	During the meetings of the assessment team the additional quality data were reviewed and further information was requested.
March 2022	The applicant’s response letter was received.

* Trade names are not prequalified by WHO. This is the national medicines regulatory authority’s responsibility.

May 2022	During the meetings of the assessment team the additional quality data were reviewed and further information was requested.
May 2022	The sites relevant for the bioequivalence study were inspected for compliance with WHO requirements for GLP and GCP.
June 2022	The manufacturers of the APIs were inspected for compliance with WHO requirements for GMP.
July 2022	The applicant's response letter was received.
July and August 2022	The additional quality data were reviewed and further information was requested.
September 2022	The applicant's response letter was received.
September 2022	During the meeting of the assessment team the additional quality data were reviewed and further information was requested.
October 2022	The applicant's response letter was received.
December 2022	The additional quality data were reviewed and further information was requested.
January 2023	The applicant's response letters were received.
January 2023	The quality data were reviewed and found to comply with the relevant WHO requirements.
March 2023	The manufacturer of the FPP was inspected for compliance with WHO requirements for GMP.
January 2023	Product dossier accepted (quality assurance)
30 July 2023	[MA169 trade name] was included in the list of prequalified medicinal products.

II. GENERAL CONDITIONS FOR THE PREQUALIFICATION

1. Manufacturer and Inspection status

Manufacturer of the finished product and responsible for batch release

Universal Corporation Limited
Club Road, Plot No. 13777
P.O.Box 1748-00902
Kikuyu,
Kenya.
Tel: +254 20 2693835 / 20 2693836
Email: info@ucl.co.ke

Inspection status

The sites inspected were found to be in compliance with WHO requirements for GMP, GLP and GCP.

2. (Advice on) Conditions or restrictions regarding supply and use

Medicinal product subject to medical prescription.

Further information is available at:

<https://extranet.who.int/pqweb/medicines/prequalified-lists/finished-pharmaceutical-products>